BRPI0512516A - composto ou um sal, enanciÈmero, racemato, diastereÈmero ou mistura de diastereÈmeros farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto - Google Patents

composto ou um sal, enanciÈmero, racemato, diastereÈmero ou mistura de diastereÈmeros farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto

Info

Publication number
BRPI0512516A
BRPI0512516A BRPI0512516-2A BRPI0512516A BRPI0512516A BR PI0512516 A BRPI0512516 A BR PI0512516A BR PI0512516 A BRPI0512516 A BR PI0512516A BR PI0512516 A BRPI0512516 A BR PI0512516A
Authority
BR
Brazil
Prior art keywords
compound
racemate
diastereomer
diastereomers
enantiomer
Prior art date
Application number
BRPI0512516-2A
Other languages
English (en)
Inventor
Xinchao Chen
Christopher Lawrence Cioffi
Sean Richard Dinn
Ana Maria Escribano
Maria Carmen Fernandez
Todd Fields
Robert Jason Herr
Nathan Bryan Mantlo
Eva Maria Martin De La Nava
Ana Isabel Mateo Herranz
Saravanan Parthasarathy
Xiaodong Wang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35056992&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0512516(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BRPI0512516A publication Critical patent/BRPI0512516A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

COMPOSTO OU UM SAL, ENANCIÈMERO, RACEMATO, DIASTEREÈMERO OU MISTURA, DE DIASTEREÈMEROS FARMACEUTICAMIENTE ACEITáVEL COMPOSIçãO FARMACêUTICA, E, USO DE UM COMPOSTO A invenção refere-se a compostos da Fórmula (I): em que n, m, p, Y, R¬1¬, R¬2¬, R¬3a¬, R¬3b¬, R¬4¬, R¬5¬, e R¬6¬ são como definidos aqui, e a suas composições farmacêuticas e a métodos de uso.
BRPI0512516-2A 2004-06-24 2005-06-23 composto ou um sal, enanciÈmero, racemato, diastereÈmero ou mistura de diastereÈmeros farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto BRPI0512516A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US58270804P 2004-06-24 2004-06-24
US62724104P 2004-11-12 2004-11-12
US66486205P 2005-03-24 2005-03-24
PCT/US2005/022389 WO2006002342A1 (en) 2004-06-24 2005-06-23 Compounds and methods for treating dyslipidemia

Publications (1)

Publication Number Publication Date
BRPI0512516A true BRPI0512516A (pt) 2008-03-11

Family

ID=35056992

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0512523-5A BRPI0512523A (pt) 2004-06-24 2005-06-22 composto ou um sal, enanciÈmero, racemato, diastereÈmero ou mistura de diastereÈmeros farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto
BRPI0512516-2A BRPI0512516A (pt) 2004-06-24 2005-06-23 composto ou um sal, enanciÈmero, racemato, diastereÈmero ou mistura de diastereÈmeros farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0512523-5A BRPI0512523A (pt) 2004-06-24 2005-06-22 composto ou um sal, enanciÈmero, racemato, diastereÈmero ou mistura de diastereÈmeros farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto

Country Status (26)

Country Link
US (3) US20080269284A1 (pt)
EP (3) EP1761521A1 (pt)
JP (2) JP2008504266A (pt)
KR (1) KR20070041452A (pt)
CN (1) CN1972932B (pt)
AT (1) ATE528304T1 (pt)
AU (2) AU2005267436A1 (pt)
BR (2) BRPI0512523A (pt)
CA (2) CA2570688A1 (pt)
CR (1) CR8831A (pt)
CY (1) CY1112124T1 (pt)
DK (1) DK1761522T3 (pt)
EA (2) EA200700119A1 (pt)
EC (2) ECSP067098A (pt)
ES (1) ES2372291T3 (pt)
HR (1) HRP20110761T1 (pt)
IL (2) IL180276A0 (pt)
MA (2) MA28730B1 (pt)
MX (2) MXPA06014716A (pt)
NO (2) NO20070468L (pt)
NZ (1) NZ550978A (pt)
PL (1) PL1761522T3 (pt)
PT (1) PT1761522E (pt)
RS (1) RS52064B (pt)
SI (1) SI1761522T1 (pt)
WO (2) WO2006012093A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037796A1 (en) * 2003-10-08 2005-04-28 Eli Lilly And Company Compounds and methods for treating dyslipidemia
WO2005097805A1 (en) * 2004-03-26 2005-10-20 Eli Lilly And Company Compounds and methods for treating dyslipidemia
UA90269C2 (ru) 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
AU2005267436A1 (en) 2004-06-24 2006-02-02 Eli Lilly And Company Compounds and methods for treating dyslipidemia
WO2007107843A1 (en) * 2006-03-22 2007-09-27 Pfizer Products Inc. Methods of treatment with cetp inhibitors
TW200808731A (en) 2006-03-30 2008-02-16 Tanabe Seiyaku Co A process for preparing tetrahydroquinoline derivatives
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
DE102007005045B4 (de) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2157190B1 (en) 2007-05-17 2017-05-03 EA Pharma Co., Ltd. Method of measuring the activity of lipid-modified enzyme
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
AR077208A1 (es) 2009-06-30 2011-08-10 Lilly Co Eli Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam
MX2012001729A (es) 2009-08-26 2012-06-13 Sanofi Sa Nuevos hidratos cristalinos de fluoroglicosido heteroaromatico, productos farmaceuticos que comprenden estos compuestos, y su empleo.
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683701B1 (de) 2011-03-08 2014-12-24 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
ES2683350T3 (es) * 2011-07-08 2018-09-26 Novartis Ag Método para tratar la aterosclerosis en sujetos con alto nivel de triglicéridos
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
HUE035391T2 (en) * 2012-06-11 2018-05-02 Tacurion Process for the preparation of 4,4,7-trifluoro-1,2,3,4-tetrahydro-5H-1-benzazepine compound and intermediate of synthesis
WO2014012401A1 (zh) * 2012-07-16 2014-01-23 上海恒瑞医药有限公司 苯并七元杂环类衍生物、其制备方法及其在医药上的应用
DK3102212T3 (en) * 2014-02-05 2019-02-11 Dezima Pharma B V Cholesteryl ester transfer protein (CETP) inhibitors and pharmaceutical compositions comprising the inhibitor for use in the treatment or prevention of cardiovascular disease
CN103833637B (zh) * 2014-03-31 2016-01-06 武汉武药制药有限公司 一种制备依塞曲匹（Evacetrapib）中间体的方法
DK3307734T3 (da) 2015-06-09 2020-01-27 Abbvie Inc Nukleære receptormodulatorer (ror) til behandling af inflammatoriske og autoimmune sygdomme
WO2016198908A1 (en) 2015-06-09 2016-12-15 Abbvie Inc. Ror nuclear receptor modulators
KR102919209B1 (ko) 2018-08-10 2026-01-28 다이아핀 테라퓨틱스, 엘엘씨 트리-펩타이드 그리고 대사, 심장혈관 및 염증성 장애의 치료
EP4719392A2 (en) * 2023-06-01 2026-04-08 Tenvie Therapeutics Inc. Compounds, compositions, and methods
CN117263810B (zh) * 2023-09-19 2026-01-27 上海凌凯科技股份有限公司 还原硝基苯制备苯胺类化合物以及选择性碘代苯胺类化合物的方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2402506A1 (fr) * 1977-09-09 1979-04-06 Guelennec Emile Le Cisaille pour la decoupe de ferrailles de grandes dimensions
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
CO5271716A1 (es) * 1999-11-30 2003-04-30 Pfizer Prod Inc Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
ATE316957T1 (de) * 2001-04-30 2006-02-15 Pfizer Prod Inc Verbindungen verwendbar als zwischenprodukte für 4-aminochinolinderivate
BR0306208A (pt) 2002-08-30 2004-10-13 Japan Tobacco Inc Compostos de dibenzilamina e seu uso farmacêutico
AU2003277285B2 (en) 2002-10-04 2007-12-13 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
JP2006523218A (ja) 2003-03-04 2006-10-12 高砂香料工業株式会社 光学活性アミン類の製造方法
US20040204450A1 (en) * 2003-03-28 2004-10-14 Pfizer Inc Quinoline and quinoxaline compounds
WO2005037796A1 (en) 2003-10-08 2005-04-28 Eli Lilly And Company Compounds and methods for treating dyslipidemia
WO2005097805A1 (en) 2004-03-26 2005-10-20 Eli Lilly And Company Compounds and methods for treating dyslipidemia
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
AU2005267436A1 (en) 2004-06-24 2006-02-02 Eli Lilly And Company Compounds and methods for treating dyslipidemia
WO2006069162A1 (en) 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds and their pharmaceutical compositions
AR077208A1 (es) * 2009-06-30 2011-08-10 Lilly Co Eli Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam

Also Published As

Publication number Publication date
CN1972932B (zh) 2011-06-29
NO20070470L (no) 2007-03-26
WO2006002342A1 (en) 2006-01-05
BRPI0512523A (pt) 2008-03-11
CY1112124T1 (el) 2015-11-04
IL180277A (en) 2011-08-31
WO2006012093A1 (en) 2006-02-02
CA2570673C (en) 2013-01-29
MA28730B1 (fr) 2007-07-02
JP2008504266A (ja) 2008-02-14
DK1761522T3 (da) 2012-01-02
EA200700120A1 (ru) 2007-06-29
ECSP067095A (es) 2007-01-26
AU2005267436A1 (en) 2006-02-02
US7786108B2 (en) 2010-08-31
AU2005258241A1 (en) 2006-01-05
US20080269284A1 (en) 2008-10-30
EA012585B1 (ru) 2009-10-30
US20070244095A1 (en) 2007-10-18
MA28729B1 (fr) 2007-07-02
HRP20110761T1 (hr) 2011-11-30
EP1761522A1 (en) 2007-03-14
AU2005258241B2 (en) 2011-08-25
IL180276A0 (en) 2007-07-04
HK1104528A1 (en) 2008-01-18
KR20070041452A (ko) 2007-04-18
PL1761522T3 (pl) 2012-03-30
RS52064B (sr) 2012-06-30
ATE528304T1 (de) 2011-10-15
JP4836945B2 (ja) 2011-12-14
CR8831A (es) 2008-11-13
ECSP067098A (es) 2007-01-26
ES2372291T3 (es) 2012-01-18
MXPA06014706A (es) 2007-03-12
US20100204207A1 (en) 2010-08-12
EP1761522B1 (en) 2011-10-12
JP2008504277A (ja) 2008-02-14
IL180277A0 (en) 2007-07-04
CA2570688A1 (en) 2006-02-02
CN1972932A (zh) 2007-05-30
NO20070468L (no) 2007-03-12
CA2570673A1 (en) 2006-01-05
SI1761522T1 (sl) 2012-02-29
EP1761521A1 (en) 2007-03-14
MXPA06014716A (es) 2007-03-12
NZ550978A (en) 2010-08-27
EA200700119A1 (ru) 2007-10-26
PT1761522E (pt) 2011-12-21
EP2479175A1 (en) 2012-07-25

Similar Documents

Publication Publication Date Title
BRPI0512516A (pt) composto ou um sal, enanciÈmero, racemato, diastereÈmero ou mistura de diastereÈmeros farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto
ATE406360T1 (de) Antagonisten der opioidrezeptoren
BRPI0518459A2 (pt) composto ou um sal farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, uso de um composto, e, processo para preparar o composto ou um sal farmaceuticamente aceitÁvel do mesmo
BRPI0417717A (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0508966A (pt) composto, composição farmacêutica, e, uso de um composto
GEP20115359B (en) Fused cyclic compounds
ATE377589T1 (de) 6-substituierte nikotinamidderivate als opioidrezeptorantagonisten
WO2006025979A3 (en) Modulators of nuclear receptors
BRPI0417714A (pt) composto, composição farmacêutica, e, uso de um composto
WO2007016392A3 (en) Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
ATE397605T1 (de) Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol
NO20045486L (no) Nye forbindelser og deres anvendelse
ATE556074T1 (de) Neue imidazoä1,5-aüpyridinderivate, verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten
WO2007146856A3 (en) Substituted gamma lactams as therapeutic agents
DE60302157D1 (de) Opioidrezeptorantagonisten
MY139612A (en) Benzoxazine derivatives as 5-th6 modulators and uses thereof
MXPA05009523A (es) Derivados de quinolina/benzoxazinona y sus usos.
WO2006036981A3 (en) Small molecule modulators of cytokine activity
TW200626567A (en) Benzoxazine and quinoxaline derivatives and uses
FR2894579B1 (fr) Derives diaryltriazolmethylamine, leur preparation et leur application en therapeutique.
WO2006076569A3 (en) Bicyclic heterocycles as cannabinoid receptor modulators
WO2006052893A3 (en) Substituted pyrrolidone compounds as ep4 agonists
WO2006056877A3 (en) Diazepine oxazolidinones as antibacterial agents
TH104559A (th) สารประกอบพิแรโซลีน

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 7.4 NA RPI NO 2437 DE 19/09/2017 POR TER SIDO INDEVIDA.